Trials / Completed
CompletedNCT06136325
Treatment of Anal Fistulas With Obsidian RFT®
Treatment of Anal Fistulas With Obsidian RFT® - a Retrospective Analysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 18 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The study conducted a retrospective analysis from January 2018 to December 2022 on patients who received anal fistula closure with Obsidian RTF® at the Department of General Surgery, Medical University of Vienna.
Detailed description
Anal fistulas present a significant challenge in colorectal surgery, featuring abnormal passages between the anal canal and surrounding tissues. Traditional treatments, while effective, may risk damaging the anal sphincter complex and subsequent fecal incontinence. Sphincter-preserving techniques like autologous compound platelet-rich fibrin foam have gained popularity, offering potential for better functional outcomes in anal fistula treatment. In this context, our retrospective study aims to evaluate the efficacy and safety of autologous compound platelet-rich fibrin foam, specifically Obsidian RFT®, analyzing its success in fistula closure and functional outcomes, thus contributing to the advancement of sphincter-preserving methods in anal fistula management. The study conducted a retrospective analysis from January 2018 to December 2022 on patients who received anal fistula closure with Obsidian RTF® at the Department of General Surgery, Medical University of Vienna. Clinical diagnosis, complemented by radiographic imaging, was employed to confirm inconclusive cases. Demographic, comorbidity, fistula characteristics, and postoperative data were collected from electronic records.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Obsidian RFP anal fistula surgery | Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF® |
Timeline
- Start date
- 2018-01-17
- Primary completion
- 2022-12-31
- Completion
- 2023-10-27
- First posted
- 2023-11-18
- Last updated
- 2023-11-18
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT06136325. Inclusion in this directory is not an endorsement.